Rays Power Infra announced closure of INR 127 Crore Equity Capital Fund Raise - CMR Green Technologies Limited Announced its Initial Public Offer (IPO) to open on June 3, 2026 At the Price Band of the Offer has been fixed at ₹ 182 to ₹ 192 per Equity Share - PM Modi's 12 Years: From Self-Reliant India to 'Make for the World' - Fadnavis, Chavan List Achievements - Sadbhavana Old Age Home needs ‘Mavtar’ The world’s largest ‘Vinubhai Bachubhai Nagrecha Campus’ Sadbhavana Old Age Home (Rajkot) requires childless, destitute, bedridden mavtar. Free admission will be given - Tata Realty and Salesforce Collaborate to Set New Benchmarks in AI-Led Customer Experience - Yami Gautam Dhar joins Surya Hospitals’ “The Amber Promise for Women’s Health” initiative during the launch of the Amber Wing at Santacruz Mumbai - Celebrating Innovation: HDFC SKY Shares Perspectives on India’s F&O Market Growth on National Technology Day - Rahul Shewale, Madhoo, Ashok Dhamankar and Mujtaba Aziz Naza Unveil the Latest Issue of ‘Society Interiors & Design’ Featuring Ar. Kavita & Ar. Soyuz Talib - Eugenix Hair Sciences celebrate 10 Years of Business Expansion Backed by 20,000+ Success Patients From a modest clinic in the Himalayan foothills to a name trusted across continents, Eugenix’s decade-long journey reflects a quiet revolution built on trust, innovation and patient-first care - VFS Global‑led consortium wins major citizen services contract to drive technology‑enabled transformation of 60 Model Sub‑Registrar Offices across Maharashtra - Godrej Enterprises Group advances India’s aero engine capabilities through precision engineering and global trust

Apollo Cancer Centre Leads the Way with India’s First LungLife Screening Program to Combat Lung Cancer

Apollo Cancer Centre Leads the Way with India’s First LungLife Screening Program to Combat Lung Cancer

Navi Mumbai, 28th November 2024 (GNI):– Apollo Cancer Centres (ACCs), a leader in cutting-edge cancer care, has launched India’s first LungLife Screening Program for early detection of lung cancer. This groundbreaking initiative aims to combat lung cancer, which accounts for 5.9% GNI/) all cancers and 8.1% of cancer-related deaths in India. Early detection aids in better treatment outcomes and enhances the survival rate.  

GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC) show that lung cancer remains the leading cause of cancer death, with an estimated 1.8 million deaths (18%) in 2020. The LungLife Screening Program aims at individuals who have the highest risk for lung cancer such as: (i) people between the age group of 50 and 80 years, (ii) asymptomatic (no signs or symptoms of lung cancer), (iii) individuals with a significant history of smoking and (iv) people with family history of lung cancers.

Early screening through low-dose computed tomography (LDCT) can aid in early detection and significantly improve survival rates. Yet approximately 80% of high-risk individuals have never discussed screening with their healthcare providers. Enhancing communication and awareness around lung cancer screening is vital to enable early diagnosis and save lives, especially among the high-risk population.

Dr Jayalakshmi TK – Sr Consultant Pulmonology Apollo Hospitals Navi Mumbai, said “The introduction of Apollo Cancer Centre’s Lung-Life Screening Program marks a pivotal step in addressing the alarming rise of lung cancer in India. With this comprehensive screening program, we focus on early-stage detection, where the chances of effective treatment and recovery are exponentially higher. The program leverages state-of-the-art low-dose CT scans, ensuring accurate diagnoses while prioritizing patient safety. Together, we are not just treating cancer but transforming lives through timely interventions and holistic care tailored to individual needs.”

Dr Pavankumar Biraris- Consultant Pulmonology, Apollo Hospitals Navi Mumbai, said, “Lung cancer remains one of the deadliest cancers globally, but early detection notably enhances survival chances. Our Lung-Life Screening Program aims to identify high-risk individuals early, using advanced low-dose CT technology, which minimizes radiation exposure while maximizing diagnostic precision. This program is particularly impactful for individuals with a history of smoking, passive smoking exposure, or a family history of lung cancer. By detecting lung cancer at a treatable stage, we empower patients with better treatment outcomes and build a renewed hope for a healthier future.” 

Dr Rajesh Shinde – Consultant HPB, GI & Thoracic Oncology & Robotic Surgery, Apollo Cancer Centre, Navi Mumbai, said, “Lung cancer is a silent threat, often detected only when it has advanced, thereby, making early detection a critical intervention. With the launch of the Lung-Life Screening Program, Apollo Cancer Centre is revolutionizing the approach to lung cancer care. This program combines precision diagnostics with patient-focused care to detect it early, significantly improving survival rates. Our initiative demonstrates that proactive healthcare can save lives, offering patients the best chance for recovery and reinforcing our commitment to redefining excellence in cancer treatment.”

Dr. Jyoti Bajpai, Lead medical and Precision Oncology, at Apollo Cancer Centre, Navi Mumbai, said, “We are proud to be the first in India to launch the Lung-Life Screening Program, a ground-breaking initiative that reflects Apollo Cancer Centre’s leadership in oncology care. Our goal is not just to save lives but to empower individuals with the knowledge and tools to take control of their health.”

Apollo Cancer Centres remains steadfast in its mission to elevate the standards of cancer care and awareness in India. With the introduction of the Lung Life Screening Program, ACCs hopes to inspire nationwide action and collaboration in the fight against lung cancer.ends GNI

Be the first to comment on "Apollo Cancer Centre Leads the Way with India’s First LungLife Screening Program to Combat Lung Cancer"

Leave a comment

Your email address will not be published.


*